Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-202A (Sacubitril/Valsartan) in essential hypertension
NCT06643819Phase 3Recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in essential hypertension, sponsored by Chong Kun Dang Holdings. Started Oct 2024; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06643819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643819.